Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126451 | 1.00 | MAPT (0.51) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL6133189 | 0.92 | MAPT (0.56) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL6075627 | 0.89 | SIRT6 (0.49) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL12408720 | 0.83 | GPR119 (0.49) | — | |
| SCHEMBL3178582 | 0.81 | NPY5R (0.40) | LMNA | |
| SCHEMBL6326158 | 0.81 | GFER (0.40) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL25364252 | 0.80 | NOTUM (0.47) | CYP2C9ADRB1 | |
| SCHEMBL19221743 | 0.80 | MAPT (0.58) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL1856887 | 0.79 | ALDH1A1 (0.42) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL16569991 | 0.77 | MAPT (0.66) | MAPTALDH1A1POLBCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209464-A1 | Process for preparing optically active 1- (4-nitrophenyl) -3-pyrrolidinol derivatives, and chiral para-phenylenediamines containing a pyrrolidinyl group | L'OREAL S.A. (FR) | 2005-09-22 | — | — | US | disclosed |
| EP-1535904-A2 | Process for the preparation of optically active 1-(4-nitrophenyl)-3-pyrrolidinole derivatives, paraphenylenediaines comprising chiral pyrrolidinyl groups | L'OREAL (FR) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209464-A1 | Process for preparing optically active 1- (4-nitrophenyl) -3-pyrrolidinol derivatives, and chiral para-phenylenediamines containing a pyrrolidinyl group | KRT18, PPOX, PKM | MAPT 1132/4885ALDH1A1 340/4885POLB 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.